| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 156, Issue 8 2909-2917, Copyright © 1996 by American Association of Immunologists
ARTICLES |
TF Gajewski, F Fallarino, C Uyttenhove and T Boon
Ludwig Institute for Cancer Research, Brussels, Belgium.
Although transfection to express any of a multitude of immunomodulatory molecules can lead to the rejection of murine tumors in vivo, it is not clear which of these cofactors are truly important for the induction of tumor-specific CTL. Examination of the costimuli used by the host immune response during the normal rejection of immunogenic tumors should reveal critical cofactors for CTL differentiation in vivo. The involvement of a host B7 family costimulator molecule in the rejection of immunogenic tum- variants of the mastocytoma P815 was explored. Rejection of immunogenic P815 variants was prevented by mCTLA4 gamma 3, a fusion protein between the extracellular domain of murine CTLA4 and the Fc portion of a murine IgG3 Ab, indicating the importance of a CTLA4 ligand provided by the host in the rejection of B7- tumors. Tumor rejection also was prevented by mCTLA4 gamma 3 in the absence of CD4+ cells, suggesting that CD8+ lymphocytes may receive direct costimulation by B7 in vivo. Finally, although living transfectants of poorly immunogenic P1.HTR cells expressing B7-1 or B7-2 were equally rejected by syngeneic mice, if delivered as multiple injections of irradiated cells, only B7-1 transfectants successfully induced CTL activity and protected against living tumor challenge. Our results indicate that a CTLA4 ligand is normally involved in the generation of CD8+ CTL against tumor Ag and suggest that immunization with irradiated B7-1-transfected tumor cells may be superior to immunization with irradiated B7-2 transfectants as an approach to tumor Ag vaccination in patients.
This article has been cited by other articles:
|
|
 |
|
  I. J. Thomas, L. G. Petrich de Marquesini, R. Ravanan, R. M. Smith, S. Guerder, R. A. Flavell, D. C. Wraith, L. Wen, and F. S. Wong CD86 Has Sustained Costimulatory Effects on CD8 T Cells J. Immunol., November 1, 2007; 179(9): 5936 - 5946. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Pejawar-Gaddy and M. A. Alexander-Miller Ligation of CD80 Is Critical for High-Level CD25 Expression on CD8+ T Lymphocytes J. Immunol., October 1, 2006; 177(7): 4495 - 4502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. E. Brown, C. Blank, J. Kline, A. K. Kacha, and T. F. Gajewski Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection J. Immunol., October 1, 2006; 177(7): 4521 - 4529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Wille, E. N. Villegas, L. Craig, R. Peach, and C. A. Hunter Contribution of Interleukin-12 (IL-12) and the CD28/B7 and CD40/CD40 Ligand Pathways to the Development of a Pathological T-Cell Response in IL-10-Deficient Mice Infect. Immun., December 1, 2002; 70(12): 6940 - 6947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bilsborough, C. Uyttenhove, D. Colau, P. Bousso, C. Libert, B. Weynand, T. Boon, and B. J. Van den Eynde TNF-Mediated Toxicity After Massive Induction of Specific CD8+ T Cells Following Immunization of Mice with a Tumor-Specific Peptide J. Immunol., September 15, 2002; 169(6): 3053 - 3060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mencacci, C. Montagnoli, A. Bacci, E. Cenci, L. Pitzurra, A. Spreca, M. Kopf, A. H. Sharpe, and L. Romani CD80+Gr-1+ Myeloid Cells Inhibit Development of Antifungal Th1 Immunity in Mice with Candidiasis J. Immunol., September 15, 2002; 169(6): 3180 - 3190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Hwang, W. B. Sweatt, I. E. Brown, C. Blank, T. F. Gajewski, J. A. Bluestone, and M.-L. Alegre Cutting Edge: Targeted Ligation of CTLA-4 In Vivo by Membrane-Bound Anti-CTLA-4 Antibody Prevents Rejection of Allogeneic Cells J. Immunol., July 15, 2002; 169(2): 633 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Belladonna, J.-C. Renauld, R. Bianchi, C. Vacca, F. Fallarino, C. Orabona, M. C. Fioretti, U. Grohmann, and P. Puccetti IL-23 and IL-12 Have Overlapping, but Distinct, Effects on Murine Dendritic Cells J. Immunol., June 1, 2002; 168(11): 5448 - 5454. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. LaBelle, C. A. Hanke, B. R. Blazar, and R. L. Truitt Negative effect of CTLA-4 on induction of T-cell immunity in vivo to B7-1+, but not B7-2+, murine myelogenous leukemia Blood, March 15, 2002; 99(6): 2146 - 2153. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Suvas, V. Singh, S. Sahdev, H. Vohra, and J. N. Agrewala Distinct Role of CD80 and CD86 in the Regulation of the Activation of B Cell and B Cell Lymphoma J. Biol. Chem., March 1, 2002; 277(10): 7766 - 7775. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Rudolf, S. C. Fausch, D. M. Da Silva, and W. M. Kast Human Dendritic Cells Are Activated by Chimeric Human Papillomavirus Type-16 Virus-Like Particles and Induce Epitope-Specific Human T Cell Responses In Vitro J. Immunol., May 15, 2001; 166(10): 5917 - 5924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Markiewicz, F. Fallarino, A. Ashikari, and T. F. Gajewski Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A Int. Immunol., May 1, 2001; 13(5): 625 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Dembic, J.-A. Rottingen, J. Dellacasagrande, K. Schenck, and B. Bogen Phagocytic dendritic cells from myelomas activate tumor-specific T cells at a single cell level Blood, May 1, 2001; 97(9): 2808 - 2814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Gajewski, F. Fallarino, P. E. Fields, F. Rivas, and M.-L. Alegre Absence of CTLA-4 Lowers the Activation Threshold of Primed CD8+ TCR-Transgenic T Cells: Lack of Correlation with Src Homology Domain 2-Containing Protein Tyrosine Phosphatase J. Immunol., March 15, 2001; 166(6): 3900 - 3907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Chan, D. J. Lee, A. Schubert, C. M. Tang, B. Crain, S. P. Schoenberger, and M. Corr The Roles of MHC Class II, CD40, and B7 Costimulation in CTL Induction by Plasmid DNA J. Immunol., March 1, 2001; 166(5): 3061 - 3066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Kacha, F. Fallarino, M. A. Markiewicz, and T. F. Gajewski Spontaneous Rejection of Poorly Immunogenic P1.HTR Tumors by Stat6-Deficient Mice J. Immunol., December 1, 2000; 165(11): 6024 - 6028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhan, A. J. Corbett, J. L. Brady, R. M. Sutherland, and A. M. Lew CD4 Help-Independent Induction of Cytotoxic CD8 Cells to Allogeneic P815 Tumor Cells Is Absolutely Dependent on Costimulation J. Immunol., October 1, 2000; 165(7): 3612 - 3619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Griffin, D. K. Hong, P. O. Holman, K.-M. Lee, M. J. Whitters, S. M. O'Herrin, F. Fallarino, M. Collins, D. M. Segal, T. F. Gajewski, et al. Blockade of T Cell Activation Using a Surface-Linked Single-Chain Antibody to CTLA-4 (CD152) J. Immunol., May 1, 2000; 164(9): 4433 - 4442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Martin-Fontecha, M. Moro, M. C. Crosti, F. Veglia, G. Casorati, and P. Dellabona Vaccination with Mouse Mammary Adenocarcinoma Cells Coexpressing B7-1 (CD80) and B7-2 (CD86) Discloses the Dominant Effect of B7-1 in the Induction of Antitumor Immunity J. Immunol., January 15, 2000; 164(2): 698 - 704. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fallarino and T. F. Gajewski Cutting Edge: Differentiation of Antitumor CTL In Vivo Requires Host Expression of Stat1 J. Immunol., October 15, 1999; 163(8): 4109 - 4113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sturmhoefel, K. Lee, G. S. Gray, J. Thomas, R. Zollner, M. O'Toole, H. Swiniarski, A. Dorner, and S. F. Wolf Potent Activity of Soluble B7-IgG Fusion Proteins in Therapy of Established Tumors and as Vaccine Adjuvant Cancer Res., October 1, 1999; 59(19): 4964 - 4972. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. Martin, J. G. Frelinger, and J. P.-Y. Ting Combination Gene Therapy with CD86 and the MHC Class II Transactivator in the Control of Lung Tumor Growth J. Immunol., June 1, 1999; 162(11): 6663 - 6670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vink, G. Warnier, F. Brombacher, and J.-C. Renauld Interleukin 9-induced In Vivo Expansion of the B-1 Lymphocyte Population J. Exp. Med., May 3, 1999; 189(9): 1413 - 1423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. L. Motte, A. H. Sharpe, J. A. Bluestone, and M. B. Mokyr Host B7-1 and B7-2 Costimulatory Molecules Contribute to the Eradication of B7-1-Transfected P815 Tumor Cells Via a CD8+ T Cell-Dependent Mechanism J. Immunol., April 15, 1999; 162(8): 4817 - 4823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. La Motte, A. H. Sharpe, J. A. Bluestone, and M. B. Mokyr Importance of B7-1-Expressing Host Antigen-Presenting Cells for the Eradication of B7-2 Transfected P815 Tumor Cells J. Immunol., December 15, 1998; 161(12): 6552 - 6558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Fields, R. J. Finch, G. S. Gray, R. Zollner, J. L. Thomas, K. Sturmhoefel, K. Lee, S. Wolf, T. F. Gajewski, and F. W. Fitch B7.1 Is a Quantitatively Stronger Costimulus Than B7.2 in the Activation of Naive CD8+ TCR-Transgenic T Cells J. Immunol., November 15, 1998; 161(10): 5268 - 5275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Sigal, H. Reiser, and K. L. Rock The Role of B7-1 and B7-2 Costimulation for the Generation of CTL Responses In Vivo J. Immunol., September 15, 1998; 161(6): 2740 - 2745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mutis, E. Schrama, C. J.M. Melief, and E. Goulmy CD80-Transfected Acute Myeloid Leukemia Cells Induce Primary Allogeneic T-Cell Responses Directed at Patient Specific Minor Histocompatibility Antigens and Leukemia-Associated Antigens Blood, September 1, 1998; 92(5): 1677 - 1684. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nakajima, T. Kodama, S. Morimoto, M. Azuma, K. Takeda, H. Oshima, S.-i. Yoshino, H. Yagita, and K. Okumura Antitumor Effect of CD40 Ligand: Elicitation of Local and Systemic Antitumor Responses by IL-12 and B7 J. Immunol., August 15, 1998; 161(4): 1901 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fallarino, P. E. Fields, and T. F. Gajewski B7-1 Engagement of Cytotoxic T Lymphocyte Antigen 4 Inhibits T Cell Activation in the Absence of CD28 J. Exp. Med., July 1, 1998; 188(1): 205 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Challita-Eid, M. L. Penichet, S.-U. Shin, T. Poles, N. Mosammaparast, K. Mahmood, D. J. Slamon, S. L. Morrison, and J. D. Rosenblatt A B7.1-Antibody Fusion Protein Retains Antibody Specificity and Ability to Activate Via the T Cell Costimulatory Pathway J. Immunol., April 1, 1998; 160(7): 3419 - 3426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Mokyr, T. V. Kalinichenko, L. Gorelik, and J. A. Bluestone Importance of the B7-2 Molecule for Low Dose Melphalan-Induced Acquisition of Tumor-Eradicating Immunity by Mice Bearing a Large MOPC-315 Tumor J. Immunol., February 15, 1998; 160(4): 1866 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dunussi-Joannopoulos, G. Dranoff, H. J. Weinstein, J. L.M. Ferrara, B. E. Bierer, and J. M. Croop Gene Immunotherapy in Murine Acute Myeloid Leukemia: Granulocyte-Macrophage Colony-Stimulating Factor Tumor Cell Vaccines Elicit More Potent Antitumor Immunity Compared With B7 Family and Other Cytokine Vaccines Blood, January 1, 1998; 91(1): 222 - 230. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Dunussi-Joannopoulos, W. Krenger, H. J. Weinstein, J. L.M. Ferrara, and J. M. Croop CD8+ T Cells Activated During the Course of Murine Acute Myelogenous Leukemia Elicit Therapeutic Responses to Late B7 Vaccines After Cytoreductive Treatment Blood, April 15, 1997; 89(8): 2915 - 2924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Dembic, K. Schenck, and B. Bogen Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells PNAS, March 14, 2000; 97(6): 2697 - 2702. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
